Integrated Cancer Research Center Symposium

Primary tabs

"Recent Advances in Cancer Nanotechnology: From Diagnostics to Therapeutics"

April 13, 2017
Engineered Biosystems Building (EBB), Rm. 1005
Georgia Tech

We are at a truly exciting crossroads in the history of cancer research where molecular biology, the computational sciences, engineering and nanotechnology are joining together in a unified effort to develop more effective cancer diagnostics and therapeutics. The benefits of this integrated approach are only beginning to be realized. The number of new technologies and devices arising from the fields of biomedical engineering and nanotechnology that have potential application to the area of cancer biology is unprecedented. The second annual ICRC mini-symposium at Georgia Tech will showcase recent advances in cancer nanotechnology by national and international experts in the field. Pre-registration is not required but space is limited. Please come early and participate in discussions with leaders in the field.


James Heath, Ph.D.
Elizabeth W. Gilloon 
Professor of Chemistry, California Institute of Technology
Professor of Molecular Medicine, University of California Los Angeles, Los Angeles, CA

Shana Kelley, Ph.D.
Departments of Pharmaceutical Sciences, Chemistry, Biochemistry,
Institute for Biomaterials and Biomedical Engineering
University of Toronto, Toronto, Canada

Adriana Haimovitz-Friedman, Ph.D.
Attending Radiation Biologist
Memorial Sloan Kettering Cancer Center, New York, NY

Susan Thomas, Ph.D.
Assistant Professor
Department of Biomedical Engineering
Georgia Institute of Technology, Atlanta, GA

Todd Sulchek, Ph.D.
The George W. Woodruff School of Mechanical Engineering 
Georgia Institute of Technology, Atlanta, GA

A. Fatih Sarioglu, Ph.D
Assistant Professor
School of Electrical and Computer Engineering 
Georgia Institute of Technology, Atlanta, GA

Symposium Agenda


  • Workflow Status:
  • Created By:
    Floyd Wood
  • Created:
  • Modified By:
    Fletcher Moore
  • Modified:

Target Audience

    No target audience selected.